OGEN vs. GTBP, DRUG, SNPX, ALZN, NEXI, PTPI, XCUR, KTRA, PCSA, and LGVN
Should you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include GT Biopharma (GTBP), Bright Minds Biosciences (DRUG), Synaptogenix (SNPX), Alzamend Neuro (ALZN), NexImmune (NEXI), Petros Pharmaceuticals (PTPI), Exicure (XCUR), Kintara Therapeutics (KTRA), Processa Pharmaceuticals (PCSA), and Longeveron (LGVN). These companies are all part of the "pharmaceutical preparations" industry.
GT Biopharma (NASDAQ:GTBP) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.
In the previous week, Oragenics had 1 more articles in the media than GT Biopharma. MarketBeat recorded 1 mentions for Oragenics and 0 mentions for GT Biopharma. Oragenics' average media sentiment score of 0.00 equaled GT Biopharma'saverage media sentiment score.
GT Biopharma received 115 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 62.84% of users gave GT Biopharma an outperform vote while only 0.00% of users gave Oragenics an outperform vote.
GT Biopharma has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
GT Biopharma has higher earnings, but lower revenue than Oragenics. GT Biopharma is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.
8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 18.7% of Oragenics shares are held by institutional investors. 10.0% of GT Biopharma shares are held by insiders. Comparatively, 24.6% of Oragenics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Oragenics' return on equity of -112.84% beat GT Biopharma's return on equity.
GT Biopharma presently has a consensus price target of $150.00, suggesting a potential upside of 4,445.45%. Given Oragenics' higher probable upside, analysts plainly believe GT Biopharma is more favorable than Oragenics.
Summary
GT Biopharma beats Oragenics on 9 of the 14 factors compared between the two stocks.
Get Oragenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oragenics Competitors List
Related Companies and Tools
